Cleveland Biolabs Inc.

Cleveland, OH • (216) 229-2251 •

Exchange and Ticker: Nasdaq: CBLI

Filing Range: 1.7M shares @ $6 to $8

Offering Price: $6

Close on First Day: $5.30

Close on 08/01/06: $5.20

Offering Size: $10.2M

Market Capitalization on 08/01/06: $60.8M

Shares Outstanding: 11.8M

Underwriter: Sunrise Securities

Co-manager: Roth Capital Partners Inc.

Company Counsel: Katten Muchin Zavis Rosenman

Manager Counsel: Mintz Levin Cohn Ferris Glovsky & Popeo

Auditor: Meaden & Moore Ltd.


Develops drugs for protection of normal tissues from exposure to radiation. The company identifies and develops new types of drugs for protection of normal tissues from exposure to radiation and other stresses, such as toxic chemicals and for cancer treatment. The company’s initial target is to develop a drug to protect humans from the effects of exposure to radiation, whether as a result of military or terrorist acts or as a result of a nuclear accident. The company says that recent acts of terrorism and the proliferation of nuclear weapons programs in rogue states have created a more immediate demand for further research and development in this area. Other potential applications of the company’s drugs include reducing the side effects of cancer treatment as well as killing tumor cells.

Venture Backers

Sunrise Financial Group Inc.

Source: Thomson Financial